Editor’s Choice
Main Category: HIV / AIDS
Also Included In: Liver Disease / Hepatitis
Article Date: 27 Apr 2012 – 14:00 PDT

email to a friend   printer friendly   opinions  

<!– rate article

Patient / Public:

Healthcare Prof:

The United States Food and Drug Administration (FDA) is updating information on Victrelis (boceprevir). The drug is used as a hepatitis C (HCV) protease inhibitor. It is combined with various ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors.

The FDA is stating that it cannot recommend use of the drug at this time, because it appears to reduce effectiveness of other medications and has been seen to cause HCV and HIV to increase in the bloodstream. This is known as the viral load, and obviously leads to the diseases becoming more potent and aggressive.

Ritonavir-boosted HIV protease inhibitors include ritonavir-boosted Reyataz (atazanavir), ritonavir-boosted Prezista (darunavir), and Kaletra (lopinavir/ritonavir). Ritonavir is an HIV protease inhibitor that is taken as a small dose along with other HIV protease inhibitors in order to increase their levels in the blood and make them more effective. This is known as ritonavir boosting.

The FDA states that patients should not simply stop taking their medicines on FDA advice, but must seek consultation with their physician as to the best course of action for their particular situation.

The FDA also issues advice for healthcare professionals who are treating patients with chronic HCV and HIV, using Victrelis where the patient was taking antiretroviral therapy in the form of ritonavir-boosted protease inhibitors. The patient’s response to the drug combination should be closely monitored for any unexpected increase in virus levels.

The FDA has already issued a warning about Victerlis in Feb. 2012, stating that using Victrelis while taking any one of the three ritonavir-boosted HIV protease inhibitors appeared to reduce the desired blood levels of both medicines. Obviously this is undesirable because lower blood levels of the drug can lead to less effective treatment and higher viral load.

The FDA goes on to remind healthcare professionals that there is only limited information on the use and effectiveness of Victrelis and ritonavir-boosted HIV protease inhibitors when they are used together in patients infected with both HIV and HCV. A small clinical trial studied treatment of patients with both HIV and HCV, where the HCV infection was treated with either peginterferon/ribavirin or boceprivir plus peginterferon/ribavirin and whose HIV infection was treated with ritonavir-boosted atazanavir, ritonavir-boosted darunavir, lopinavir/ritonavir, or raltegravir (Isentress).

People who took boceprevir plus peginterferon/ribavirin were more likely to have undetectable HCV viral loads 12 weeks after completing HCV treatment than individuals who received peginterferon/ribavirin alone. Overall, seven patients had HIV virologic rebound, 3/64 randomized to receive boceprevir with peginterferon/ribavirin and 4/34 randomized to peginterferon/ribavirin alone. Preliminary results of this clinical trial were presented at the 19th Conference on Retroviruses and Opportunistic Infections on March 6, 2012. The clinical trial abstract is online.

The FDA says that the findings of the drug-drug interaction study and the clinical trial, has caused it to revise the Victrelis drug label to state that co-administration of Victrelis with ritonavir-boosted Reyataz (atazanavir), ritonavir-boosted Prezista (darunavir), or Kaletra (lopinavir/ritonavir) to patients infected with both chronic HCV and HIV is not recommended at this time.

There is a larger clinical trial in process, to look at HCV treatment with boceprevir and peginterferon/ribavirin, where patients have both HCV and HIV and are taking antiretroviral treatment that use ritonavir-boosted HIV protease inhibitors. The FDA intends to update any new information it has about the co-use of the drugs.

Written by Rupert Shepherd

Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations

Please use one of the following formats to cite this article in your essay, paper or report:



Please note: If no author information is provided, the source is cited instead.

Add Your Opinion On This Article

‘FDA Update Safety Information On HIV Drug Victerlis (boceprevir)’

Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

Privacy Policy |
Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.

Article source: http://www.medicalnewstoday.com/articles/244721.php


One Response to FDA Update Safety Information On HIV Drug Victerlis (boceprevir)

  1. [...] this link: FDA Update Safety Information On HIV Drug Victerlis (boceprevir … This entry was posted in hiv and tagged form, hcv, healthcare-professionals, hiv, patient, [...]

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

TEAM 25:40
Help become part of the solution by running for 25:40. Whether you are a novice or an elite athlete, story you can elevate your experience above just a race -- you can race to give an at-risk child in rural South Africa a #FightingChance to rise above poverty, disease and violence.
The Sub-Saharan AIDS epidemic has a devastating effect on millions of families. Consider that 5.5 million adults and children live with HIV/AIDS in South Africa alone. Discover the hard facts about poverty, there disease and violence, and help become a part of the solution.
25:40’s current focus is on children living in rural areas of South Africa’s Eastern Cape. We have selected this area as our place of initial focus due to its extreme poverty, patient lack of resources and lack of attention from the outside world.